XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML

导出原文传递

翻译打印收藏纠错

作者： Carter, B.Z. ^[1] ; Mak, D.H. ^[2] ; Morris, S.J. ^[3] ; Borthakur, G. ^[4] ; Estey, E. ; Byrd, A.L. ; Konopleva, M. ; Kantarjian, H. ; Andreeff, M.

作者单位： Aegera Therapeutics Inc., Montreal, QC, Canada ^[1] Department of Stem Cell Transplantation and Cellular Therapy, Unit 448, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, United States ^[2] Seattle Cancer Care Alliance, University of Washington, Seattle, WA, United States ^[3] Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX, United States ^[4]

关键词 AML Antisense oligonucleotide AEG35156 Apoptosis Clinical trial XIAP

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交